研究

工藤正俊, 西川博嘉, 土谷 薫

臨床的疑問を免疫学的基礎から読み解く. 特別鼎談

工藤正俊

アテゾリズマブ＋ベバシズマブ併用療法後の二次治療としてのレンバチニブ

工藤正俊, 青木智子

FDG-PETは肝細胞癌に対する免疫療法のimaging biomarkerとなり得るか

工藤正俊, 岡井夏輝

切除不能肝細胞癌におけるcancer-free達成のための複合免疫療法とTACE併用の治療戦略

Takuya Matsubara, Satoru Hagiwara, Naoshi Nishida, Naoya Omaru, Akihiro Yoshida, Tomoki Yamamoto, Yoriaki Komeda, Mamoru Takenaka, Masatoshi Kudo

Observational pilot study of switching from entecavir to tenofovir alafenamide in patients with chronic hepatitis B

Junji Furuse, Namiki Izumi, Kenta Motomura, Yoshitaka Inaba, Yoshio Katamura, Yasuteru Kondo, Kazuhisa Yabushita, Toshiyuki Matsuoka, Katsuaki Motoyoshi, Masatoshi Kudo

Long-Term Survival of Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in Real-World Clinical Practice.

Jinlin Hou, Thomas Berg, Arndt Vogel, Teerha Piratvisuth, Jörg Trojan, Enrico N De Toni, Masatoshi Kudo, Katarina Malinowsky, Peter Findeisen, Johannes Kolja Hegel …

Comparative evaluation of multimarker algorithms for early-stage HCC detection in multicenter prospective studies.

Atsushi Hiraoka, Masatoshi Kudo, Toshifumi Tada, Takeshi Hatanaka, Satoru Kakizaki, Kazuya Kariyama, Hideko Ohama, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi …

The current status of tumor markers as biomarkers in the era of immunotherapy for hepatocellular carcinoma: alpha-fetoprotein alone is not sufficient.

Masatoshi Kudo, Tatsuya Yamashita, Richard S Finn, Peter R Galle, Michel Ducreux, Ann-Lii Cheng, Kaoru Tsuchiya, Naoya Sakamoto, Shuhei Hige, Ryosuke Take …

Depth and Duration of Response Are Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150.

Xue-Qi Li, Guang-Wen Cheng, Iwaki Akiyama, Xian-Jue Huang, Jing Liang, Li-Yun Xue, Yi Cheng, Masatoshi Kudo, Hong Ding

Attenuation imaging: Diagnostic differences in hepatic steatosis for chronic hepatitis B vs metabolic dysfunction-associated steatotic liver disease patients.

Mamoru Takenaka, Masatoshi Kudo

What has changed and remained the same in the past 55 years regarding the prediction and prevention of postendoscopic retrograde cholangiopancreatography pancreatitis?

Masatoshi Kudo

Systemic Therapy Combined with Locoregional Therapy in Intermediate-stage Hepatocellular Carcinoma.

George Lau, Bruno Sangro, Ann-Lii Cheng, Masatoshi Kudo, Robin Kate Kelley, Won Young Tak, Antonio Gasbarrini, Maria Reig, Ho Yeong Lim, David Tougeron …

Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial.

Thomas Yau, Peter R Galle, Thomas Decaens, Bruno Sangro, Shukui Qin, Leonardo G da Fonseca, Hatim Karachiwala, Jean-Frederic Blanc, Joong-Won Park, Edward Gane …

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.

Yasunori Minami, Katsutoshi Sugimoto, Hidekatus Kuroda, Naohisa Kamiyama, Chikara Ogawa, Masatoshi Kudo

Differentiating between hepatocellular carcinoma and its mimickers using contrast-enhanced ultrasound with perflubutane microbubbles.

Masatoshi Kudo, Masafumi Ikeda, Hiroshi Aikata, Kazushi Numata, Hiroyuki Marusawa, Tetsuya Hosaka, Naoya Kato, Masayuki Kurosaki, Manabu Morimoto, Tatsuya Yamashita …

First-Line Lenvatinib plus Pembrolizumab for Hepatocellular Carcinoma: Post hoc Analysis of Japanese Patients from the Phase 3 LEAP-002 Trial.

Yoon Jun Kim, Philippe Merle, Richard S Finn, Masatoshi Kudo, Heinz-Josef Klümpen, Ho Yeong Lim, Masafumi Ikeda, Alessandro Granito, Gianluca Masi, René Gerolami …

Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study.

Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi …

Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinoma.

Yasuhiro Masuta, Naoya Omaru, Yasuo Otsuka, Sho Masaki, Kosuke Minaga, Hajime Honjo, Tomohiro Watanabe, Masatoshi Kudo

Methotrexate-Associated Systemic Lymphadenopathy Exhibiting a Marked Elevation of the Serum IgG4 Concentrations.

Tomohiro Watanabe, Masatoshi Kudo

Roles of Deubiquitinases OTUD3 and OTUD5 in Inflammatory Bowel Diseases.

Ryotaro Ogawa, Junichiro Kawamura, Edward T Ashworth, Soo Bin Park, David J Hall, Masatoshi Kudo, Carl K Hoh, David R Vera

Multimodal tilmanocept for preoperative imaging and fluorescence-guided surgery of porcine lateral pelvic sentinel lymph nodes.

Kazuya Kariyama, Kazuhiro Nouso, Atsushi Hiraoka, Fujimasa Tada, Hideko Ohama, Hidenori Toyoda, Satoshi Yasuda, Toshifumi Tada, Kazunari Tanaka, Kunihiko Tsuji …

Evolution of Hepatocellular Carcinoma Treatment Outcomes Over Two Decades in Japan: Improvements in Early-Stage Viral Disease.

Sho Masaki, Yasuhiro Masuta, Yasuo Otsuka, Hajime Honjo, Tomohiro Watanabe, Masatoshi Kudo

Possible Involvement of the Mucosal Claudin Expression in the Healing of a Refractory Ileocecal Ulcer in a Patient with Crohn's Disease Successfully Treated with Infliximab.

Federica Lo Prinzi, Federico Rossari, Antonio De Rosa, Caterina Vivaldi, Masatoshi Kudo, Shigeo Shimose, Goki Suda, Silvia Camera, Silvia Foti, Mario Domenico Rizzato …

Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi-Center Real-World Study.

Kazuomi Ueshima, Naoshi Nishida, Satoru Hagiwara, Yasunori Minami, Hiroshi Ida, Masahiro Takita, Hirokazu Chishina, Masahiro Morita, Tomoko Aoki, Tetsutaro Hamano …

No Correlation Between Proteinuria and Renal Function in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: ARISE Study.

Koichiro Kawano, Mamoru Takenaka, Reiko Kawano, Daisuke Kagoshige, Koutaro Mine, Katsuhisa Nishi, Masatoshi Kudo

A novel clip with mantis-like claws combined with the over-the-scope clip for fistula closure.

Hidekazu Tanaka, Mamoru Takenaka, Yasuhiro Masuta, Kosuke Minaga, Koichiro Kawano, Masatoshi Kudo

A novel endoscopic lithotripsy technique for a huge common bile duct stone: endoscopic snare lithotripsy.

Pasquale Lombardi, Jung Sun Kim, Giulia F Manfredi, Ciro Celsa, Claudia A M Fulgenzi, Antonio D'Alessio, Bernardo Stefanini, Niraj C Doshi, Emily Warmington, Thomas U Marron …

Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study.

Kazuomi Ueshima, Kaoru Tsuchiya, Tatsuya Yamashita, Shigeo Shimose, Kazushi Numata, Yuzo Kodama, Shinji Itoh, Yasuhito Tanaka, Hidekatsu Kuroda, Kazuyoshi Ohkawa …

Atezolizumab Plus Bevacizumab for TACE-Unsuitable Intermediate-Stage HCC Beyond Up-To-7 Criteria: Final Analysis of REPLACEMENT.

Masatoshi Kudo

Lancet Commission 2025 Calls for Urgent Global Action: 60% of Liver Cancers Are Preventable.

Kentaro Yamao, Mamoru Takenaka, Akihiro Yoshida, Takuya Ishikawa, Hiroki Kawashima, Masatoshi Kudo

Response to the letter to the editor regarding our manuscript: "Concealed pancreatic cancer in acute pancreatitis: Early MRCP and EUS surveillance improves prognosis and identifies high-risk patients".

Naoya Omaru, Masahiro Takita, Ikue Sekai, Kosuke Minaga, Satoru Hagiwara, Misa Kojima, Osamu Maenishi, Yoshihide Ueda, Tomohiro Watanabe, Masatoshi Kudo

Cytomegalovirus-induced intrahepatic cholestasis complicated by hemophagocytic syndrome in an immunocompetent adult.

Stephen Lam Chan, Richard S Finn, Julien Edeline, Sadahisa Ogasawara, Jennifer J Knox, Bruno Daniele, Baek-Yeol Ryoo, Philippe Merle, Mohamed Bouattour, Ho-Yeong Lim …

Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinoma.